Exploratory Subgroup Analyses: Why Do We Need Particular Caution?

Thomas R. Fleming, Ph.D. Professor, Dept. of Biostatistics University of Washington

* Fleming TR "Clinical Trials: Discerning Hype from Substance" *Annals of Internal Medicine* 2010; 153:400-406

Industry Sponsors

- Company profits,
 † value of stock options, promotion
- Government Sponsors
 - ~ Claims of success in advancing health care
 - ~ Leverage for ↑ in federal funding
- Journal Editors (Publication bias)
 - Academic Investigators / Caregivers
 - ~ Increased ability to publish results
 - ↑ professional stature, earlier promotion, ↑ salary

~ Desire to offer more therapeutic options to patients

....Result: Wide Spread & Significant Conflicts of Interest


An Illustration of Exploratory Analyses: Post-hoc Subgroup Analyses

Surgical Adjuvant Therapy of Colorectal Cancer

R 5-FU + Levamisole Levamisole Control


Surgical Adjuvant Therapy: Colorectal Cancer

NCCTG Trial



Years from randomization


NORTH CENTRAL TREATMENT GROUP STUDY Looking at Treatment Effect on Overall Survival



Years from Registration


Surgical Adjuvant Therapy: Colorectal Cancer

NCCTG Trial



Years from randomization


Surgical Adjuvant Therapy: Colorectal Cancer



Years from randomization

Years from randomization

INTERGROUP STUDY 0035 Looking at Treatment Effect on Overall Survival



Years from Registration

Duke's C Colon Cancer Adjuvant

Percent ↓ in	Death Rate:	<u>5-FU + Levamisole</u> Control
Analysis Group	North Cent Treatmen Group Stue (n = 162)	t Study
All patients	28%	33%
Female Male	43% 9%	15% 50%
Young Old	40% 13%	23% 41%


Confirmatory vs. Exploratory Analyses

- Hyp. Confirmation vs. Hyp. Generation
 - Post-hoc analyses & Random High Bias (new endpoints, new analyses, interim analyses subgroup analyses, covariate adjustments)
 - Illustrations and Motivation: *Baseball* & Clinical Research


An Illustration of Exploratory Analyses: Post-hoc Subgroup Analyses

Radiation Treatment in Rectal Cancer Princess Margaret Hospital


R Pre-operative R.T. Control Survival of Patients with Rectal Carcinoma Princess Margaret Hospital, Toronto (1977)




Survival of Patients with Rectal Carcinoma Exploratory Subgroup: **Dukes' Stage C Disease**



Medical Research Council (MRC) Confirmatory Trial



MRC Subgroup Analysis: Dukes' C Cases




Some Important Observations


- *P*-values are only interpretable when you understand the sampling context from which they were derived
- Random High bias is real
- Exploratory Analyses usually should be viewed to be "Hypothesis Generating"
- Confirmatory Trials greatly enhance the reliability of conclusions

Fleming TR "Clinical Trials: Discerning Hype from Substance" Annals of Internal Medicine 2010; 153:400-406

Survival of Patients with Rectal Carcinoma Exploratory Subgroup: **Dukes' Stage C Disease**



MRC Subgroup Analysis: Dukes' C Cases



"It isn't so much the things we *don't know* that get us in trouble.
It's the things we *know* that aren't so".
—Artemus Ward (1834-1867)

Thrombolytics in Acute Myocardial Infarction

GISSI (Lancet '86)
 SK reduces mortality by 20% confined to:

 anterior MI
 < 65 years
 < 6 hours from symptom onset

Thrombolytics in Acute Myocardial Infarction

• GISSI (Lancet '86) - SK reduces mortality by 20% confined to: anterior MI < 65 years < 6 hours from symptom onset - Subset restriction not confirmed by ISIS-2, ASSET, AIMS - While in ISIS-2: **Aspirin beneficial overall...**

Thrombolytics in Acute Myocardial Infarction

• GISSI (Lancet '86) - SK reduces mortality by 20% confined to: anterior MI < 65 years < 6 hours from symptom onset - Subset restriction not confirmed by ISIS-2, ASSET, AIMS - While in ISIS-2: Aspirin beneficial overall... ... yet harmful to patients with astrological signs Libra and Gemini

Bias for "Positive" Results in Clinical Trials

- Protocol Specified Clinical Trial "Primary Objective.
- Very frequent wording:
 - ~ "To *establish* that the experimental regimen

is safe and effective"

Bias for "Positive" Results in Clinical Trials

- Protocol Specified Clinical Trial "Primary Objective"
- Very frequent wording:
 - ~ "To *establish* that the experimental regimen

is safe and effective"

- Scientifically unbiased wording:
 - "To *determine whether* the experimental regimen is safe and effective"
- Regulatory Industry Statistics Workshop: (9/22/2011)
 ...Credibility of exploratory analyses...
 ...a Paradox...

- Abetimus Sodium: Reducing Renal Flare Rate in Lupus
- <u>Trial #1</u>: Time to renal flare: Minimal effect, (2p = 0.51)

- Abetimus Sodium: Reducing Renal Flare Rate in Lupus
- <u>Trial #1</u>: Time to renal flare: Minimal effect, (2p = 0.51)...exploratory *high affinity* subgroup: 2p = 0.007
- <u>Trial #2</u> conducted in *high affinity* subgroup: Time to renal flare:

- Abetimus Sodium: Reducing Renal Flare Rate in Lupus
- <u>Trial #1</u>: Time to renal flare: Minimal effect, (2p = 0.51) ...exploratory *high affinity* subgroup: 2p = 0.007
- <u>Trial #2</u> conducted in *high affinity* subgroup: Time to renal flare: Minimal non-significant effect

- Abetimus Sodium: Reducing Renal Flare Rate in Lupus
- <u>Trial #1</u>: Time to renal flare: Minimal effect, (2p = 0.51)...exploratory *high affinity* subgroup: 2p = 0.007
- <u>Trial #2</u> conducted in *high affinity* subgroup: Time to renal flare: Minimal non-significant effect ...exploratory *truncation at 12 months* is favorable
- <u>Trial #3</u> conducted in *high affinity* subgroup with prespecified *truncation at 12 months follow-up*:

- Abetimus Sodium: Reducing Renal Flare Rate in Lupus
- <u>Trial #1</u>: Time to renal flare: Minimal effect, (2p = 0.51)...exploratory *high affinity* subgroup: 2p = 0.007
- <u>Trial #2</u> conducted in *high affinity* subgroup: Time to renal flare: Minimal non-significant effect ...exploratory *truncation at 12 months* is favorable
- <u>Trial #3</u> conducted in *high affinity* subgroup with prespecified *truncation at 12 months follow-up*: ...early termination by DMC for futility.

"If you Torture Data Long Enough, They will Confess"

* Fleming TR "Clinical Trials: Discerning Hype from Substance" Annals of Internal Medicine 2010; 153:400-406

- Recognize bias resulting from strong interest to achieve "positive" results
- When refereeing journal publications, request:
 - the clinical trial protocol
 - the statistical analysis plan (SAP)
 - the clinical study report (CSR)
- The only *P*-values presented in CSRs & publications should be for α-spending analyses pre-specified in the SAP
- Recognize unreliability of Exploratory Analyses... ...generating hypotheses, but with "random high" bias
- Exploratory subgroup analyses should be presented descriptively, for example using forest plots

Some Conclusions

- For reliable evidence regarding effects by subgroups, such as evaluating effects in biomarker positive vs negative subgroups, it is important to have pre-specified hypotheses (potentially with alpha spending)
- Cautionary Note: "When it is prespecified that biomarkernegative patients should not be included in the primary analysis of treatment effect in biomarker-positive patients because of the likelihood that treatment effects would differ between the 2 subgroups, it is logically inconsistent to include biomarker-positive patients in the primary analysis of treatment effect in biomarkernegative patients." *
 - ⁴ Rothmann et al. "Testing in a Pre-specified Subgroup and the Intent-to-treat Population. *Drug Information Journal* 46(2): 175-179, 2012.